Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 8, 2008 - Issue 1
Submit an article Journal homepage
100
Views
4
CrossRef citations to date
0
Altmetric
Drug Profile

Cost–effectiveness of natalizumab in multiple sclerosis

Trygve Holmoy Department of Neurology, Ulleval University Hospital, 0407 Oslo, Norway; Institute of Immunology, Faculty of Medicine, University of Oslo, Norway. [email protected]
&
Elisabeth Gulowsen Celius Department of Neurology, Ulleval University Hospital, 0407, Oslo, Norway. [email protected]
Pages 11-21 | Published online: 09 Jan 2014

Citations (4)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Leonardo Koeser & Paul McCrone. (2013) Cost–effectiveness of natalizumab in multiple sclerosis: an updated systematic review. Expert Review of Pharmacoeconomics & Outcomes Research 13:2, pages 171-182.
Read now

Articles from other publishers (3)

Hasnat Ahmad, Ingrid van der Mei, Bruce V Taylor, Robyn M Lucas, Anne-Louise Ponsonby, Jeannette Lechner-Scott, Keith Dear, Patricia Valery, Philip M Clarke, Steve Simpson & Andrew J Palmer. (2018) Estimation of annual probabilities of changing disability levels in Australians with relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal 25:13, pages 1800-1808.
Crossref
Roger Lee Mendoza. (2013) Pharmacoeconomics and clinical trials in multiple sclerosis: baseline data from the European Union. Journal of Public Health 22:3, pages 211-218.
Crossref
Annie Hawton, James Shearer, Elizabeth Goodwin & Colin Green. (2013) Squinting Through Layers of Fog: Assessing the Cost Effectiveness of Treatments for Multiple Sclerosis. Applied Health Economics and Health Policy 11:4, pages 331-341.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.